Last reviewed · How we verify
V920 High-dose Lot
V920 High-dose Lot is a vaccine designed to prevent Ebola virus disease.
V920 High-dose Lot is a vaccine designed to prevent Ebola virus disease. Used for Prevention of Ebola virus disease in individuals at risk of infection.
At a glance
| Generic name | V920 High-dose Lot |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
The vaccine works by introducing a non-infectious component of the Ebola virus to stimulate an immune response, which can protect against future infection with the live virus.
Approved indications
- Prevention of Ebola virus disease in individuals at risk of infection
Common side effects
- Injection site pain
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- V920 High-dose Lot CI brief — competitive landscape report
- V920 High-dose Lot updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI